Relationship research between prognosis of trabeculectomy and fibroblast derived from each patient

Relationship research between prognosis of trabeculectomy and fibroblast derived from each patient - Relationship research between prognosis of trabeculectomy and fibroblast derived from each patient

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009198

Enrollment

116

Registered

2012-10-27

Start date

2012-10-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Intraocular pressure of more than 21 mmHg on maximum-tolerated medical therapy 2. Patient who has progress of visual field defect 3. Written informed consent from the patient

Exclusion criteria

Exclusion criteria: 1. Previously cataract extraction with intraocular lens implantation, trabeculectomy, or both 2. Pregnant or nursing women 3. No light perception 4. Active iris neovascularization or active proliferative retinopathy 5. Iridocorneal endothelial syndrome 6. Epithelial of fibrous downgrowth 7. Aphakia 8. Vitreous in the anterior chamber for which a vitrectomy is anticipated 9. Chronic and recurrent uveitis 10. Severe posterior blepharitis 11. Unwilling to discontinue contact lens use after surgery 12. Previous cyclodestructive procedure, scleral buckling procedure, or silicone oil present 13. Conjunctival scarring precluding from producing a bleb by previous several surgeries 14. Need glaucoma surgery combined with other ocular procedures (i.e., cataract surgery, penetrating keratoplasty, or retinal surgery), anticipated need for additional ocular surgery 15. Judged inappropriate for this study by physicians

Design outcomes

Primary

Measure	Time frame
Correlation between prognosis of trabeculectomy and resistance of fibroblast derived from each patient for mitomycin C	—

Countries

Japan

Contacts

Public ContactRyo Watanabe

Tohoku University Hospital Ophthalmology

ryo-w@oph.med.tohoku.ac.jp022-717-7294

Outcome results